EU to suspend U.S. tariff retaliation, will look for a deal with Trump by Aug. 1
Article content
″This is now the time for negotiations,″ European Commission President Ursula von der Leyen told reporters in Brussels on Sunday, after President Donald Trump sent a letter announcing new tariffs of 30 per cent on goods from the EU and Mexico starting Aug. 1.
Article content
Article content
Article content
The EU — America's biggest trading partner and the world's largest trading bloc — had been scheduled to impose ″countermeasures″ starting Monday at midnight Brussels time (6 p.m. EDT; 22:00 GMT). The EU negotiates trade deals on behalf of its 27 member countries.
Article content
Von der Leyen said those countermeasures would be delayed until Aug. 1, and that Trump's letter shows ″that we have until the first of August″ to negotiate.
Article content
″We have always been clear that we prefer a negotiated solution,″ she said. If they can't reach a deal, she said that ″we will continue to prepare countermeasures so we are fully prepared.″
Article content
A 30% tariff on EU exports would hurt businesses, consumers and patients on both sides of the Atlantic.
We will continue working towards an agreement by August 1.
At the same time, we are ready to safeguard EU interests on the basis of proportionate countermeasures.
— Ursula von der Leyen (@vonderleyen) July 12, 2025
Article content
Europe's biggest exports to the U.S. are pharmaceuticals, cars, aircraft, chemicals, medical instruments and wine and spirits.
Article content
Italian Foreign Minister Antonio Tajani was heading to Washington for talks Monday with the U.S. administration and Congress. In a statement, Tajani's office said that in his talks with EU allies before the meetings, he stressed the need to 'negotiate with one's head held high.'
Article content
The right-wing government of Premier Giorgia Meloni, the only EU leader to attend Trump's inauguration, has sought to position itself as a ' bridge' between Brussels and Washington.
Article content
Trump has said his global tariffs would set the foundation for reviving a U.S. economy that he claims has been ripped off by other nations for decades. Trump, in his letter to the EU, said the U.S. trade deficit was a national security threat.
Article content
Trump isn't satisfied with some of the draft agreements on trade, White House National Economic Council Director Kevin Hassett said on ABC News Sunday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025. On April 23, 2025, Salarius was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius' common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. On March 26, 2025, Nasdaq notified the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on The Nasdaq Stock Market. On June 16, 2025, Salarius disclosed that the Nasdaq Hearings Panel had granted an extension contingent on Salarius achieving milestones that consist of regaining compliance with the Equity Standard by early July 2025, and regaining compliance with the Minimum Bid Price Requirement by early August 2025. On January 13, 2025, Salarius announced entry into a definitive merger agreement for a business combination with Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics. Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics. About the Planned Merger The proposed transaction, if consummated, is expected to facilitate multiple value-creating inflection points with Decoy's pipeline of peptide conjugate therapeutics engineered by its IMP 3 ACT platform, which allows for the rapid computational design and manufacturing of innovative peptide conjugate therapeutics. Decoy's product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications. In addition to advancing the development of Decoy's IMP 3 ACT platform, the combined company intends to incorporate Salarius' oral small molecule protein degrader SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACS) drug candidate. The combined company will be led by Decoy's Co-founders, Chief Executive Officer Frederick 'Rick' Pierce and Chief Scientific Officer Barbara Hibner, by Decoy's Chief Business Officer Peter Marschel, Chief Technology Officer Mike Lipp, by acting Chief Medical Officer and Scientific Advisory Board Chair Shahin Gharakhanian, M.D. and by Salarius' Chief Financial Officer Mark Rosenblum. During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress with its other programs including a broad-acting antiviral against flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. Also during this time, data may be reported from an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center evaluating Salarius' seclidemstat as a potential treatment for myelodysplastic syndrome and chronic myelomonocytic leukemia in patients with limited treatment options. About Decoy Therapeutics, Inc. Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response. For more information, please visit About Salarius Pharmaceuticals Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius' product portfolio includes seclidemstat, the company's lead candidate, which is being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers underway at MD Anderson Cancer Center as a potential treatment for MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options. SP-3164, the company's IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from the National Pediatric Cancer Foundation and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit About the Proposed Transaction Definitive agreements were executed with unanimous approvals by the Boards of Directors of Salarius and Decoy. The closing consideration will consist primarily of nonvoting preferred stock of Salarius, and it is expected that following closing and a post-closing stockholder vote to approve the conversion of the preferred shares into common stock, Decoy investors would own approximately 92.4% of the outstanding shares of the merged company and Salarius stockholders would own approximately 7.6% of the outstanding shares, in each case exclusive of any shares issued in any financing, including the qualifying financing(s) necessary to consummate the merger transaction. For further details on the transaction and conditions for closing of the merger, please refer to the Form 8-Ks Salarius filed with the U.S. Securities and Exchange Commission (SEC) on each of January 13, 2025, March 8, 2025 and June 11, 2025 at Non-Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities in connection with the merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Salarius, Decoy, the proposed merger, Salarius' ability to regain compliance with the Nasdaq continued listing requirements and other matters, including without limitation, statements relating to plans and expectations relating to the business, scientific advisory board, products, including expected achievement of milestones for its lead asset and future prospects of Salarius, Decoy and the combined company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Salarius, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the conditions to the closing are not satisfied, including uncertainties as to the timing of the consummation of the proposed merger; the ability of each of Salarius and Decoy to consummate the merger; risks and uncertainties related to Salarius' ability to regain compliance with the Nasdaq continued listing standards in the requirement timeframe; risks related to the combined company's ability to satisfy the initial listing standards in the required timeframe; Salarius may not receive any additional extensions from Nasdaq if Salarius is unable to regain compliance within the required timeframe; risks related to Salarius' ability to estimate and manage its operating expenses and its expenses associated with the proposed merger pending the closing; risks that the combined company will not achieve the synergies expected from the proposed merger; risks that Salarius and the combined company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP 3 ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Salarius' actual results may vary materially from those expected or projected.
Globe and Mail
29 minutes ago
- Globe and Mail
Wall Street points lower after Trump's weekend tariff announcement; bank earnings this week
Wall Street is pointing lower before the opening bell with new tariffs announced for Europe and Mexico and as the unofficial start of earnings season get under way this week. Futures for the S&P 500, Dow Jones Industrial Average and Nasdaq each retreated by about 0.3% early Monday. An announcement over the weekend by U.S. President Donald Trump that he plans 30% tariffs on goods from Mexico and the European Union had a modest immediate impact, as analysts said they expected progress toward trade deals before next month's deadline. The EU is America's biggest business partner and the world's largest trading bloc. The U.S. decision will have repercussions for governments, companies and consumers on both sides of the Atlantic. The tariffs could make everything from French cheese to German electronics more expensive in the U.S., while destabilizing economies from Portugal to Norway. Markets in Europe are responding negatively, with Germany's DAX slumping 1% and and Paris's CAC 40 shedding 0.5%. The FTSE 100 in Britain — which is not an EU member and has already negotiated a trade deal with the U.S. — gained 0.4%. The Trump administration had initially set Wednesday as a deadline for countries to make deals with the U.S. or face heavy increases in tariffs. But with just two trade deals announced since April, the window for negotiations has been been extended to Aug. 1. In a matter of hours, some of the market's focus will turn toward banks. JPMorgan Chase, Wells Fargo and Citigroup are among the big U.S. banks due to report their results on Tuesday. Shares of Kenvue jumped nearly 6% ahead of the opening bell Monday after the former division of Johnson & Johnson said CEO Thibaut Mongon is stepping down. Kenvue, the maker of Listerine and Band-Aid brands, continues with a strategic review of the company after splitting its consumer health division from the pharmaceutical and medical device divisions in 2021. Bitcoin climbed to another all-time high, rising as much 3.6% early Monday before settling back around $121,315, according to CoinDesk. Bitcoin's price has jumped amid bullish momentum across risk assets and coincides with Congress' Crypto Week that starts Monday. Lawmakers will debate a series of bills that could define the regulatory framework for the industry. Chinese shares advanced after the government reported that exports rose last month as a truce in a tariffs war prompted a surge in orders ahead of the Aug. 1 deadline for reaching a new trade deal with Washington. Elsewhere, Hong Kong's Hang Seng gained 0.3% to 24,091.45, while the Shanghai Composite index also was up 0.3%, at 3,519.65. Tokyo's Nikkei 225 index slipped 0.3% to 39,459.62, while the Kospi in South Korea jumped 0.8% to 3,202.03. In Australia, the S&P/ASX 200 edged 0.1% lower to 8,570.40. Taiwan's benchmark lost 0.6%. In energy markets, U.S. benchmark crude oil gained $1.05 to $69.50 per barrel, approaching the $70 level for the first time since a two-day rout in late June. Brent crude, the international standard, was up $1.03 at $71.39 per barrel. The dollar ticked up to147.45 Japanese yen from 147.38 yen. The euro fell modestly to $1.1690 from $1.1692.
Globe and Mail
29 minutes ago
- Globe and Mail
Tariff-Led Volatility Ahead for Big Tech? ETFs in Focus
The tech industry may face some ups and downs in the near term, with new tariffs expected to begin in August. Gene Munster of Deepwater Asset Management told Yahoo Finance that the delayed rollout adds uncertainty, especially for the December quarter. NVIDIA and Apple are among tech firms temporarily shielded but still under scrutiny. NVIDIA continues to grapple with a ban on chip sales to China, while Apple faces pressure to shift manufacturing to the United States or face a potential 25% tariff. Semiconductors in the Crosshairs Trump has hinted at more tariffs on semiconductors — a move that could raise prices on both components and finished products, potentially hurting consumer electronics sales. According to Bob O'Donnell of TECHnalysis Research, the lack of clarity may be more damaging than the tariffs themselves, as quoted on Yahoo Finance. Should You Fear Short-Term Volatility? The rise of AI will keep driving the market up, as companies continue to spend heavily on technology and related areas. Tech companies are investing billions in data centers and AI chips to support the development of AI systems. NVDA became the first company to reach a $4 trillion market cap on July 9, driving a sharp rally in the technology sector and the AI boom. Other 'Magnificent Seven' stocks, Microsoft MSFT, Apple AAPL, Alphabet GOOGL, Meta Platforms META and Amazon AMZN, also rallied lately on the AI euphoria and easing tariff tensions after the April shock. The technology sector is among the major growth drivers for the second-quarter earnings season. There was initially significant pressure on Tech sector Q2 earnings estimates, but the negative revisions trend notably stabilized in the subsequent weeks. Long-Term Outlook: Still Strong The global shift toward digital technology has boosted e-commerce in areas like remote work, entertainment, and shopping, making the sector stronger. The fast growth of technologies such as cloud computing, big data, the Internet of Things, wearables, VR headsets, drones, virtual reality, machine learning, digital communication, blockchain, and 5G will keep driving this momentum, irrespective of the tariff threat. Cybersecurity: A Growing Priority Cybersecurity is another prominent area. Given the recent surge in the adoption of AI technology, the need for cybersecurity becomes increasingly evident. An inevitable increase in cybersecurity spending is expected, driven by rising cyberattacks and the drastic financial fallout from them. The global cybersecurity market is projected to grow at a compound annual growth rate (CAGR) of 12.9% between 2025 and 2030, according to a new study by Grand View Research. Tech ETFs in Focus Investors can thus play any dip noticed in the technology-based exchange-traded funds (ETFs) like Select Sector SPDR Technology ETF XLK, Vanguard Information Technology ETF VGT, VanEck Vectors Semiconductor ETF SMH, SPDR S&P Software & Services ETF XSW, First Trust NASDAQ Cybersecurity ETF CIBR and Global X Cloud Computing ETF CLOU in the near term. Want key ETF info delivered straight to your inbox? Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Technology Select Sector SPDR ETF (XLK): ETF Research Reports VanEck Semiconductor ETF (SMH): ETF Research Reports Alphabet Inc. (GOOGL): Free Stock Analysis Report First Trust NASDAQ Cybersecurity ETF (CIBR): ETF Research Reports Vanguard Information Technology ETF (VGT): ETF Research Reports SPDR S&P Software & Services ETF (XSW): ETF Research Reports Global X Cloud Computing ETF (CLOU): ETF Research Reports Meta Platforms, Inc. (META): Free Stock Analysis Report
